TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
Brief Summary: This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.


Options:
A: Arm Label: Lorcaserin plus Lifestyle Modification; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lorcaserin | Arm Label: Placebo plus Lifestyle Modification; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lorcaserin; Assigned to Arm(s): Lorcaserin plus Lifestyle Modification | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus Lifestyle Modification
B: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: rimonabant (SR141716); Assigned to Arm(s): N/A
D: Arm Label: NB16; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Behavioral: Ancillary therapy | Arm Label: NB32; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Behavioral: Ancillary therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Ancillary therapy | Intervention Type: DRUG; Name: Naltrexone SR 16 mg/Bupropion SR 360 mg /day; Assigned to Arm(s): NB16 | Intervention Type: DRUG; Name: Naltrexone SR 32 mg/Bupropion SR 360 mg /day; Assigned to Arm(s): NB32 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Ancillary therapy; Assigned to Arm(s): NB16, NB32, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
Brief Summary: This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.


Options:
A: Arm Label: immediate registration on islet graft list; Type: EXPERIMENTAL; Interventions: Biological: Islet Graft | Arm Label: delayed registration on islet graft list; Type: ACTIVE_COMPARATOR; Interventions: Biological: Islet Graft | Intervention Type: BIOLOGICAL; Name: Islet Graft; Assigned to Arm(s): delayed registration on islet graft list, immediate registration on islet graft list
B: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Standard glycemic control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Arm Label: Intensive glycemic control; Type: EXPERIMENTAL; Interventions: Drug: Insulin, Drug: Glimepiride, Drug: Rosiglitazone, Drug: Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Intensive glycemic control, Standard glycemic control
D: Arm Label: Semaglutide 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide 1.0 mg; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Semaglutide placebo 0.5 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Semaglutide placebo 1.0 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 0.5 mg | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Semaglutide 1.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Semaglutide placebo 0.5 mg, Semaglutide placebo 1.0 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
Brief Summary: This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.


Options:
A: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: BI 10773 low dose; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: BI 10773 | Arm Label: BI 10773 high dose; Type: EXPERIMENTAL; Interventions: Drug: BI 10773, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: BI 10773; Assigned to Arm(s): BI 10773 low dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BI 10773 high dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: T2D, Dialysis, Liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Dialysis, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Normal kidney function, Liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Normal kidney function, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Liraglutide | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): T2D, Dialysis, Liraglutide, T2D, Dialysis, Placebo, T2D, Normal kidney function, Liraglutide, T2D, Normal kidney function, Placebo
D: Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Glukose-infusion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glucose-infusion | Arm Label: Glucose-insulin infusion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glucose-insulin infusion | Intervention Type: DRUG; Name: Glucose-infusion; Assigned to Arm(s): Glukose-infusion | Intervention Type: DRUG; Name: Glucose-insulin infusion; Assigned to Arm(s): Glucose-insulin infusion

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
Brief Summary: This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.


Options:
A: Arm Label: Vildagliptin; Type: EXPERIMENTAL; Interventions: Drug: vildagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo of vildagliptin | Intervention Type: DRUG; Name: vildagliptin; Assigned to Arm(s): Vildagliptin | Intervention Type: DRUG; Name: placebo of vildagliptin; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Canagliflozin (JNJ-28431754) 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 100 mg | Arm Label: Canagliflozin (JNJ-28431754) 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 100 mg | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 300 mg
C: Arm Label: Empagliflozin; Type: EXPERIMENTAL; Interventions: Drug: Empagliflozin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
Brief Summary: This trial is conducted in Africa, Asia, Europe, and North and South America. The aim of this trial is to determine the long term effect of liraglutide on cardiovascular events in subjects with type 2 diabetes.


Options:
A: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine, 300 U/ml, Drug: Background Therapy | Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin glargine, 100 U/ml, Drug: Insulin detemir, Drug: Background Therapy | Intervention Type: DRUG; Name: Insulin glargine, 300 U/ml; Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: Insulin glargine, 100 U/ml; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Insulin detemir; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Background Therapy; Assigned to Arm(s): Standard of Care, Toujeo
B: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine, 300U/mL, Drug: Non-insulin anti-diabetic treatment | Arm Label: Tresiba; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin degludec, 100 U/mL, Drug: Non-insulin anti-diabetic treatment | Intervention Type: DRUG; Name: Insulin glargine, 300U/mL; Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: Insulin degludec, 100 U/mL; Assigned to Arm(s): Tresiba | Intervention Type: DRUG; Name: Non-insulin anti-diabetic treatment; Assigned to Arm(s): Toujeo, Tresiba
C: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1 - Insulin glargine QHS; Type: EXPERIMENTAL; Interventions: Drug: 1- Insulin glargine QHS | Arm Label: 2 - Insulin glargine QAM; Type: EXPERIMENTAL; Interventions: Drug: 2 - Insulin glargine QAM | Arm Label: 3 - NPH Insulin QHS; Type: ACTIVE_COMPARATOR; Interventions: Drug: 3 - NPH insulin QHS | Intervention Type: DRUG; Name: 1- Insulin glargine QHS; Assigned to Arm(s): 1 - Insulin glargine QHS | Intervention Type: DRUG; Name: 2 - Insulin glargine QAM; Assigned to Arm(s): 2 - Insulin glargine QAM | Intervention Type: DRUG; Name: 3 - NPH insulin QHS; Assigned to Arm(s): 3 - NPH Insulin QHS

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE III, PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY OF L GLUTAMINE THERAPY FOR SICKLE CELL ANEMIA AND SICKLE ß0-THALASSEMIA
Brief Summary: The purpose of this research is to evaluate the effects of L-glutamine as a therapy for Sickle Cell Anemia or Sickle ß0 Thalassemia as evaluated by the number of occurrences of sickle cell crises.


Options:
A: Arm Label: investigational product; Type: EXPERIMENTAL; Interventions: Drug: L-glutamine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: L-glutamine; Assigned to Arm(s): investigational product | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: L-glutamine; Type: EXPERIMENTAL; Interventions: Drug: L-glutamine | Arm Label: 100% maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: L-glutamine; Assigned to Arm(s): L-glutamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 100% maltodextrin
C: Arm Label: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arginine | Arm Label: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arginine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Arginine; Assigned to Arm(s): High Dose, Low Dose | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Vitamin D bolus; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D bolus | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D bolus; Assigned to Arm(s): Vitamin D bolus | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Brief Summary: The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine (Lu AA21004) 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Vortioxetine (Lu AA21004) 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Venlafaxine XL 225 mg; Type: OTHER; Interventions: Drug: Venlafaxine XL | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine (Lu AA21004) 10 mg, Vortioxetine (Lu AA21004) 5 mg | Intervention Type: DRUG; Name: Venlafaxine XL; Assigned to Arm(s): Venlafaxine XL 225 mg
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Vortioxetine 15 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Intervention Type: DRUG; Name: Vortioxetine; Assigned to Arm(s): Vortioxetine 10 mg, Vortioxetine 15 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine 15 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Vortioxetine 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine | Arm Label: Duloxetine 60 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Vortioxetine; Assigned to Arm(s): Vortioxetine 15 mg, Vortioxetine 20 mg | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine: 2.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Vortioxetine: 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Vortioxetine: 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Duloxetine: 60 mg; Type: OTHER; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine: 2.5 mg | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine: 5 mg | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine: 10 mg | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine: 60 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Confronting Unequal Eye Care in Pennsylvania
Brief Summary: Pt. 1 Diabetic retinopathy is a common eye condition among diabetic adults and can lead to severe vision impairment and even blindness. African Americans are more likely to have vision loss from diabetic retinopathy due to a variety of factors, including cultural barriers to care. The investigators aim to increase the rates of eye exams in diabetic African American adults by providing culturally relevant home-based interventions. These interventions will increase the knowledge about diabetes and the eyes and the awareness of ocular risks due to diabetes.

206 African American adults, over the age of 65, with diabetes will be recruited from primary care clinics at Thomas Jefferson and Temple University. Eligible patients who consent to participate will have baseline information taken about medical and ocular history, understanding of diabetes and a hemoglobin A1C level obtained. The subjects will then be randomized to one of two treatment conditions: Behavioral Activation or Supportive Therapy, each of which will be delivered over 4 sessions. Behavioral Activation will consist of educational materials, referral assistance for eye clinics, and addressing patient specific barriers to care. Supportive Therapy will consist of supportive but non-directional interaction with the patient exploring the impact of aging and diabetes on the patient's life. The investigators hypothesize that more patients who receive Behavioral Activation will have a dilated fundus exam (the primary outcome variable), understand the risks of diabetic complications and feel less depression then subjects who receive Supportive Therapy.


Options:
A: Arm Label: Pt. 1 Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation | Arm Label: Pt. 1 Supportive Therapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Supportive Therapy | Intervention Type: BEHAVIORAL; Name: Behavioral Activation; Assigned to Arm(s): Pt. 1 Behavioral Activation | Intervention Type: BEHAVIORAL; Name: Supportive Therapy; Assigned to Arm(s): Pt. 1 Supportive Therapy
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Electronic feedback system on diabetes care | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Electronic feedback system on diabetes care; Assigned to Arm(s): Intervention
C: Arm Label: Integrated Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Behavioral Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Integrated Behavioral Care; Assigned to Arm(s): Integrated Behavioral Intervention
D: Arm Label: Mobile Insulin Titration Intervention; Type: EXPERIMENTAL; Interventions: Other: Mobile Insulin Titration Intervention | Arm Label: Current Best Practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Mobile Insulin Titration Intervention; Assigned to Arm(s): Mobile Insulin Titration Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Confronting Unequal Eye Care in Pennsylvania
Brief Summary: Pt. 1 Diabetic retinopathy is a common eye condition among diabetic adults and can lead to severe vision impairment and even blindness. African Americans are more likely to have vision loss from diabetic retinopathy due to a variety of factors, including cultural barriers to care. The investigators aim to increase the rates of eye exams in diabetic African American adults by providing culturally relevant home-based interventions. These interventions will increase the knowledge about diabetes and the eyes and the awareness of ocular risks due to diabetes.

206 African American adults, over the age of 65, with diabetes will be recruited from primary care clinics at Thomas Jefferson and Temple University. Eligible patients who consent to participate will have baseline information taken about medical and ocular history, understanding of diabetes and a hemoglobin A1C level obtained. The subjects will then be randomized to one of two treatment conditions: Behavioral Activation or Supportive Therapy, each of which will be delivered over 4 sessions. Behavioral Activation will consist of educational materials, referral assistance for eye clinics, and addressing patient specific barriers to care. Supportive Therapy will consist of supportive but non-directional interaction with the patient exploring the impact of aging and diabetes on the patient's life. The investigators hypothesize that more patients who receive Behavioral Activation will have a dilated fundus exam (the primary outcome variable), understand the risks of diabetic complications and feel less depression then subjects who receive Supportive Therapy.


Options:
A: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Procedure: Ophthalmic Telemedicine | Arm Label: Traditional Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Ophthalmic Telemedicine; Assigned to Arm(s): Telemedicine
B: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A
C: Arm Label: Pt. 1 Behavioral Activation; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Activation | Arm Label: Pt. 1 Supportive Therapy; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Supportive Therapy | Intervention Type: BEHAVIORAL; Name: Behavioral Activation; Assigned to Arm(s): Pt. 1 Behavioral Activation | Intervention Type: BEHAVIORAL; Name: Supportive Therapy; Assigned to Arm(s): Pt. 1 Supportive Therapy
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Toolkit | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Toolkit; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: C